480 related articles for article (PubMed ID: 26763445)
1. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
[TBL] [Abstract][Full Text] [Related]
2. TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention.
Mahnke K; Enk AH
J Invest Dermatol; 2016 Jan; 136(1):9-11. PubMed ID: 26763417
[TBL] [Abstract][Full Text] [Related]
3. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
4. TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells.
Zhang D; Hu W; Xie J; Zhang Y; Zhou B; Liu X; Zhang Y; Su Y; Jin B; Guo S; Zhuang R
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3085-3098. PubMed ID: 29960041
[TBL] [Abstract][Full Text] [Related]
5. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
[TBL] [Abstract][Full Text] [Related]
6. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
[TBL] [Abstract][Full Text] [Related]
7. Contribution of inhibitory receptor TIGIT to NK cell education.
He Y; Peng H; Sun R; Wei H; Ljunggren HG; Yokoyama WM; Tian Z
J Autoimmun; 2017 Jul; 81():1-12. PubMed ID: 28438433
[TBL] [Abstract][Full Text] [Related]
8. CD155T/TIGIT Signaling Regulates CD8
He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
[TBL] [Abstract][Full Text] [Related]
9. TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro.
Zhang C; Wang Y; Xun X; Wang S; Xiang X; Hu S; Cheng Q; Guo J; Li Z; Zhu J
J Immunother; 2020 Oct; 43(8):236-243. PubMed ID: 32804915
[TBL] [Abstract][Full Text] [Related]
10. A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function.
Hoogi S; Eisenberg V; Mayer S; Shamul A; Barliya T; Cohen CJ
J Immunother Cancer; 2019 Sep; 7(1):243. PubMed ID: 31500665
[TBL] [Abstract][Full Text] [Related]
11. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
[TBL] [Abstract][Full Text] [Related]
12. Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells.
Tahara S; Okumura G; Matsuo T; Shibuya A; Shibuya K
Int Immunol; 2024 Apr; 36(6):317-325. PubMed ID: 38289706
[TBL] [Abstract][Full Text] [Related]
13. The TIGIT/CD226 axis regulates human T cell function.
Lozano E; Dominguez-Villar M; Kuchroo V; Hafler DA
J Immunol; 2012 Apr; 188(8):3869-75. PubMed ID: 22427644
[TBL] [Abstract][Full Text] [Related]
14. Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathway.
Ma B; Duan X; Zhou Q; Liu J; Yang X; Zhang D; Yang S; Du Y; Li H; Su C
J Cell Mol Med; 2019 Jul; 23(7):4514-4522. PubMed ID: 31090213
[TBL] [Abstract][Full Text] [Related]
15. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
[TBL] [Abstract][Full Text] [Related]
16. CD155/TIGIT signaling regulates the effector function of tumor-infiltrating CD8+ T cell by NF-κB pathway in colorectal cancer.
Li S; Ding J; Wang Y; Wang X; Lv L
J Gastroenterol Hepatol; 2022 Jan; 37(1):154-163. PubMed ID: 34734434
[TBL] [Abstract][Full Text] [Related]
17. TX99 Is a Neutralizing Monoclonal Antibody Against Mouse TIGIT.
Nakamura Y; Naito K; Yamashita-Kanemaru Y; Komori D; Hirochika R; Shibuya A; Shibuya K
Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):105-109. PubMed ID: 29648914
[TBL] [Abstract][Full Text] [Related]
18. TIGIT Enhances Antigen-Specific Th2 Recall Responses and Allergic Disease.
Kourepini E; Paschalidis N; Simoes DC; Aggelakopoulou M; Grogan JL; Panoutsakopoulou V
J Immunol; 2016 May; 196(9):3570-80. PubMed ID: 27016609
[TBL] [Abstract][Full Text] [Related]
19. CD226 and TIGIT Cooperate in the Differentiation and Maturation of Human Tfh Cells.
Yasutomi M; Christiaansen AF; Imai N; Martin-Orozco N; Forst CV; Chen G; Ueno H
Front Immunol; 2022; 13():840457. PubMed ID: 35273617
[TBL] [Abstract][Full Text] [Related]
20. Blocking TIGIT/CD155 signalling reverses CD8
Liu L; Wang A; Liu X; Han S; Sun Y; Zhang J; Guo L; Zhang Y
J Transl Med; 2022 Jun; 20(1):280. PubMed ID: 35729552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
